Seattle Genetics starts Phase II cancer studies

Seattle Genetics (Bothell, Wash.) began two U.S. Phase II studies of its SGN-15 monoclonal antibody chemically linked to doxorubicin in patients with advanced breast breast and advanced colorectal can...